Skip to main content
. 2013 Sep 10;2(9):e121. doi: 10.1038/mtna.2013.45

Figure 4.

Figure 4

In vivo therapeutic targeting of Bcl-2 by nanoliposomal siRNA inhibits growth of ER(+) MCF-7 tumors and increases the activity of chemotherapy in an orthotopic xenograft model in mice. (a) About 2 weeks after tumor cell injection, mice-bearing equal size of MCF-7 tumors were randomly assigned to groups (n = 6) and treated with either NL-Bcl-2-siRNA or NL-control siRNA alone (0.15 mg siRNA/kg, i.v, twice a week) or in combination with doxorubicin (3 mg/kg, i.p, once a week) for 4 weeks. Mice treated with NL-Bcl-2 siRNA alone and NL-Bcl-2 siRNA and doxorubicin had significantly smaller tumor xenografts when compared with the control group (P = 0.014 and P = 0.006, respectively) (*P < 0.05). The representative tumors from each treatment group is shown below the chart. (b) Mice treated with NL-Bcl-2 siRNA (4 weeks) showed marked inhibition of Bcl-2 protein in MCF-7 tumors. Tumors were collected at the end of 4 weeks of treatment (a) and analyzed by western blot.